



Tuesday, February 18

9:30 AM – 11:00 AM

Room 33A

Sophion Bioscience A/S

Characterization of the Rapidly Desensitizing $\alpha 7$ Nicotinic Acetylcholine Receptor on the Qube, Nav1.1 Assays on Automated Electrophysiology Platforms and Developing NMDA Assays on the Qube System

Successful ion channel drug discovery requires the integration of multiple technologies and workflows. Sophion Bioscience is a leader in automated patch clamp technology, providing medium to high throughput, automated patch clamp to the pharmaceutical industry and universities. The QPatch and Qube are fully automated patch clamp systems, executing simultaneous 8, 16, 48 or 384 parallel patch clamp recordings in conjunction with computer controlled liquid handling and on-board cell handling. Sophion partners with other biotech companies to create robust, ion channel and electrophysiological workflows for drug development for ion channel targets. During this workshop, three industry speakers will provide insight into the use of these systems in the drug discovery process. Dr Sung Hoon Park will present Qube data to show the characterization of rapidly desensitizing $\alpha 7$ nicotinic acetylcholine receptor on the Qube. Next, Dr Shanti Amagasu from Amgen will present data from Amgen's Nav1.1 work on automated electrophysiological platforms. Finally, Dr Abigail Marklew will present on the development of NMDA Assays on the Qube system.

Speakers

Sung Hoon Park, Field Application Scientist, Sophion Bioscience A/S

Shanti Amagasu, Senior Scientist, Amgen

Abigail Marklew, Scientist, Charles River Laboratories